dd-cfDNA and GEP in heart-transplantation

Published: 2 February 2023| Version 2 | DOI: 10.17632/cpyj7v99rj.2
Nicholas Rodgers


Our research hypothesis is that matched results from the Prospera™ and AlloSure® donor derived cell-free DNA assays intended to detect acute rejection in single-organ heart transplant patients correlate with each other. Each unique UCSD ID represents an individual single-organ heart transplant patient who received an endomyocardial biopsy at UC San Diego Health between October 2020 and January 2022. A unique "De-identified Sample ID" is assigned to each Prospera™ sample which were collected at the time of biopsy, and matched to an AlloSure® (dd-cfDNA) and AlloMap® (gene expression profiling) sample at most 14 days prior to the biopsy where applicable. The results of the dd-cfDNA assays are provided as a donor fraction percentage and the AlloMap® results are provided as a score from 0-40. We were able to determine that statistically significant correlation existed between the results of the two assays using logistic regression. Using mixed-effects logistic regression, we observed that a subject's demographic characteristics were also important co-predictors of AR when using AlloSure® and Prospera™ results as the primary predictor. Future clinical outcomes data are also provided for each sample, with a positive value indicating that the outcome was noted in UC San Diego Health medical records since the initial sample collection. Future de-novo DSA outcomes were also collected from medical records for each sample but were not included in the "Combined Future Outcomes" column as de-novo DSA is not considered to be a clinical event by itself.



University of California San Diego, University of California San Diego Health System


Heart Transplantation, Cardiology


National Center for Advancing Translational Sciences


National Center for Advancing Translational Sciences